Drug delivery systems: Entering the mainstream

被引：3589

作者：

Allen, TM ^{[1
]}

Cullis, PR

机构：

[1] Univ Alberta, Dept Pharmacol, Edmonton, AB T6G 2H7, Canada

[2] Univ British Columbia, Dept Biochem & Mol Biol, Vancouver, BC V6T 1Z3, Canada

[3] Inex Pharmaceut Corp, Burnaby, BC V5J 5J8, Canada

来源：

SCIENCE | 2004年 / 303卷 / 5665期

关键词：

D O I：

10.1126/science.1095833

中图分类号：

O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];

学科分类号：

07 ; 0710 ; 09 ;

摘要：

Drug delivery systems (DDS) such as lipid- or polymer-based nanoparticles can be designed to improve the pharmacological and therapeutic properties of drugs administered parenterally. Many of the early problems that hindered the clinical applications of particulate DDS have been overcome, with several DDS formulations of anticancer and antifungal drugs now approved for clinical use. Furthermore, there is considerable interest in exploiting the advantages of DDS for in vivo delivery of new drugs derived from proteomics or genomics research and for their use in ligand-targeted therapeutics.

引用

页码：1818 / 1822

页数：5

共 56 条

[41]

SAMUELS BL, 1987, CANCER TREAT REP, V71, P971

[42] Host factors influencing the preferential localization of sterically stabilized liposomes in Klebsiella pneumoniae-infected rat lung tissue [J].

Schiffelers, RM ;

Storm, G ;

Bakker-Woudenberg, IAJM .

PHARMACEUTICAL RESEARCH, 2001, 18 (06) :780-787

[43] Influence of cholesterol on the association of plasma proteins with liposomes [J].

Semple, SC ;

Chonn, A ;

Cullis, PR .

BIOCHEMISTRY, 1996, 35 (08) :2521-2525

[44] Selective activation of anticancer prodrugs by monoclonal antibody-enzyme conjugates [J].

Senter, PD ;

Springer, CJ .

ADVANCED DRUG DELIVERY REVIEWS, 2001, 53 (03) :247-264

[45]

Seymour LW, 1998, INT J ONCOL, V12, P1217

[46]

Siena S, 2003, ONCOL REP, V10, P715

[47] A comparative economic analysis of pegylated liposomal doxorubicin versus topotecan in ovarian cancer in the USA and the UK [J].

Smith, DH ;

Adams, JR ;

Johnston, SRD ;

Gordon, A ;

Drummond, MF ;

Bennett, CL .

ANNALS OF ONCOLOGY, 2002, 13 (10) :1590-1597

[48] Role of complement activation in hypersensitivity reactions to doxil and HYNICPEG liposomes: Experimental and clinical studies [J].

Szebeni, J ;

Baranyi, L ;

Savay, S ;

Milosevits, J ;

Bunger, R ;

Laverman, P ;

Metselaar, JM ;

Storm, G ;

Chanan-Khan, A ;

Liebes, L ;

Muggia, FM ;

Cohen, R ;

Barenholz, Y ;

Alving, CR .

JOURNAL OF LIPOSOME RESEARCH, 2002, 12 (1-2) :165-172

[49]

Tardi P, 2000, CANCER RES, V60, P3389

[50] Myths concerning the use of cationic liposomes in vivo [J].

Templeton, NS .

EXPERT OPINION ON BIOLOGICAL THERAPY, 2003, 3 (01) :57-69

← 1 2 3 4 5 6 →